MicroRNAs and polycystic kidney disease

Lama Noureddine, Sachin Hajarnis, Vishal Patel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) - the miR-17∼92 cluster and miR-200s - in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.

Original languageEnglish (US)
JournalDrug Discovery Today: Disease Models
Volume10
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Polycystic Kidney Diseases
MicroRNAs
Gene Dosage
Cysts
Cyst Fluid
Growth
Chronic Kidney Failure
Kidney
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

MicroRNAs and polycystic kidney disease. / Noureddine, Lama; Hajarnis, Sachin; Patel, Vishal.

In: Drug Discovery Today: Disease Models, Vol. 10, No. 3, 2013.

Research output: Contribution to journalArticle

Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal. / MicroRNAs and polycystic kidney disease. In: Drug Discovery Today: Disease Models. 2013 ; Vol. 10, No. 3.
@article{178ece8ce2ce43089a1da25d5e6eba9b,
title = "MicroRNAs and polycystic kidney disease",
abstract = "Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) - the miR-17∼92 cluster and miR-200s - in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.",
author = "Lama Noureddine and Sachin Hajarnis and Vishal Patel",
year = "2013",
doi = "10.1016/j.ddmod.2013.10.001",
language = "English (US)",
volume = "10",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - MicroRNAs and polycystic kidney disease

AU - Noureddine, Lama

AU - Hajarnis, Sachin

AU - Patel, Vishal

PY - 2013

Y1 - 2013

N2 - Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) - the miR-17∼92 cluster and miR-200s - in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.

AB - Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) - the miR-17∼92 cluster and miR-200s - in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.

UR - http://www.scopus.com/inward/record.url?scp=84904061085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904061085&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2013.10.001

DO - 10.1016/j.ddmod.2013.10.001

M3 - Article

VL - 10

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

IS - 3

ER -